Black Rock Inc. Nuvectis Pharma, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 83,412 shares of NVCT stock, worth $410,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,412

Previous 372,721 77.62%

Holding current value

$410,387

Previous $3.06 Million 82.76%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$5.98 - $8.25 $1.73 Million - $2.39 Million	-289,309 Reduced 77.62%	83,412 $527,000
Q1 2024 May 10, 2024	SELL	$6.69 - $11.0 $101,487 - $166,870	-15,170 Reduced 3.91%	372,721 $3.06 Million
Q4 2023 Feb 13, 2024	BUY	$7.85 - $11.78 $223,285 - $335,070	28,444 Added 7.91%	387,891 $3.24 Million
Q3 2023 Nov 13, 2023	BUY	$12.89 - $16.29 $579,482 - $732,333	44,956 Added 14.29%	359,447 $4.63 Million
Q2 2023 Aug 11, 2023	BUY	$12.62 - $18.4 $3.8 Million - $5.54 Million	300,935 Added 2219.94%	314,491 $5.02 Million
Q1 2023 May 12, 2023	BUY	$7.32 - $14.37 $24,851 - $48,786	3,395 Added 33.41%	13,556 $177,000
Q4 2022 Feb 13, 2023	SELL	$6.7 - $7.74 $25,741 - $29,737	-3,842 Reduced 27.44%	10,161 $76,000
Q3 2022 Nov 14, 2022	BUY	$7.09 - $13.0 $48,247 - $88,465	6,805 Added 94.54%	14,003 $100,000
Q2 2022 Aug 12, 2022	SELL	$7.02 - $20.44 $4,731 - $13,776	-674 Reduced 8.56%	7,198 $80,000
Q1 2022 May 12, 2022	BUY	$3.25 - $9.1 $25,584 - $71,635	7,872 New	7,872 $59,000

Others Institutions Holding NVCT

# of Institutions

Shares Held

1.65M

Call Options Held

Put Options Held

View Full List

About Nuvectis Pharma, Inc.

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $72M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

More about NVCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account